Core D. The Neuropathology Core performs diagnostic evaluations and quantitative analyses on brain tissue collected at autopsy of participants in the Mayo Alzheimer Disease Research Center (ADRC) and related projects, in particular the Alzheimer Disease Patient Registry (ADPR). The Core also provides support to research projects of the ADRC and to other investigators at the Mayo Clinic. The neuropathology data is communicated to the Biostatistics Core and to the National Alzheimer Coordinating Center (NACC).
The specific aims of the NP Coreare: 1. Perform brain autopsies on participants of the Mayo ADRC in a timely fashion and according to protocol. 2. Provide neuropathologic evaluations and collect neuropathologic data using standardized methods for gross dissection and neurohistologic staining. a. Cooperate with neuroradiology in the acquisition of post-mortem MRI scans of hemi-brains. b. Dissect brains according to a standardized protocol, and photograph all sections. Score the severity of cerebrovascular pathology, and measure and sample macroscopic lesions. c. Use histological methods, including silver stains and immunohistochemistry for tau and Ap to collect standardized pathologic data on all cases. d. Perform immunostaining with antibodies to a-synuclein on all cases. In cases with Lewy bodies, assign a diagnosis according to the Consortium for Dementia with Lewy Bodies. e. Perform immunostaining with antibodies to TDP-43 on all cases, and when positive on the screening section, subtype and map the distribution of TDP-43 pathology. f. Consensus on clinicopathologic diagnoses are made at videoconferences held twice a month. g. Provide neuropathological data to the National Alzheimer Coordinating Center (NACC). 3. Store brain tissue and brain derived material (e.g., DNA) and provide clinically and pathologically well- characterized tissue samples, DNA or data to investigators of ADRC research projects and ADRC pilot projects as well as to qualified outside investigators.

Public Health Relevance

The Neuropathology Core provides a final diagnosis (the""""""""gold standard"""""""") for the patients enrolled in the study and is a repository of data and tissue for research purposes. Neuropathologic studies provide quality control and advance understanding of human neurologic disorders with the goals of improving diagnostic accuracy and understanding the cause of these disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG016574-12
Application #
8065951
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
12
Fiscal Year
2010
Total Cost
$212,005
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Wilmoth, Kristin; LoBue, Christian; Clem, Matthew A et al. (2018) Consistency of traumatic brain injury reporting in older adults with and without cognitive impairment. Clin Neuropsychol 32:524-529
Jones, David T; Knopman, David S; Graff-Radford, Jonathan et al. (2018) In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology 90:e947-e954
Ting, Simon Kang Seng; Foo, Heidi; Chia, Pei Shi et al. (2018) Dyslexic Characteristics of Chinese-Speaking Semantic Variant of Primary Progressive Aphasia. J Neuropsychiatry Clin Neurosci 30:31-37
Wennberg, Alexandra M V; Lesnick, Timothy G; Schwarz, Christopher G et al. (2018) Longitudinal Association Between Brain Amyloid-Beta and Gait in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci 73:1244-1250
Wennberg, Alexandra M V; Hagen, Clinton E; Edwards, Kelly et al. (2018) Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. Int J Geriatr Psychiatry 33:1114-1120
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Sahoo, Aradhana; Bejanin, Alexandre; Murray, Melissa E et al. (2018) TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia. J Alzheimers Dis 64:1227-1233

Showing the most recent 10 out of 1014 publications